Illumina has appointed Matt Posard to senior vice president and general manager of its newly created Translational and Consumer Genomics business segment (see story, this issue). Posard was previously Illumina's vice president of global sales. Before joining the company, he served as regional sales director and director of marketing at Biosite, and has also held marketing positions at Gen-Probe. He holds a BA in quantitative economics and decision science from the University of California, San Diego.
Knome has made several new hires to its management team and scientific advisory board.
Martin Tolar will become the firm's CEO, replacing Jorge Conde, who will become chief strategy officer and continue to serve on the board of directors (see story, this issue). Previously, Tolar served as CEO of Normoxys, where he helped advance the company's cancer therapeutics to clinical development. He has also served as chief scientific officer and chief business officer at CoMentis, and has held a variety of positions at Pfizer in its clinical development, strategic partnerships, and business development divisions. He served as assistant professor in the department of neurology at Yale University School of Medicine and as a research fellow at Massachusetts General Hospital. He holds a PhD in neuroscience.
Jonas Lee, a founding member of Knome's board of directors will become chief marketing officer and head of consumer genomics. Previously, he founded and managed several companies including Redbrick Partners, Poindexter Systems, GiftCertificates.com, and Integrated Computing Engines. He has also served as a management consult with Bain & Company. He holds an MBA from Harvard Business School and a bachelor's degree from Brandeis University.
Marc Rubenfield will become the vice president of operations. Prior to joining Knome, he was responsible for the sequencing services product line, including the introduction of next-generation sequencing, at Beckman Coulter Genomics. He has also worked with Agencourt Biosciences and Genome Therapeutics Corporation.
Knome has appointed David Goldstein and Yaniv Erlich to its scientific advisory board.
Goldstein is a professor of molecular genetics and microbiology, a professor of biology, and director of the Center for Human Genome Variation at Duke University. Previously he was a professor of genetics at University College London, and is also an honorary professor at the Institute of Neurology at the University College London. He holds a PhD in biological sciences from Stanford University.
Erlich is the Andria and Paul Heady Family fellow and a principal investigator at Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He holds a bachelor's degree from Tel-Aviv University in Israel and a PhD from the School of Biological Sciences at Cold Spring Harbor Laboratory.